AcquisitionOct 19, 2026Pending
Hot🇬🇧 United Kingdom
STSilence Therapeutics plcMKMerck KGaA, Darmstadt, Germany
Healthcare › Pharmaceuticals
Enterprise value$1.1BEnterprise value
AnnouncedOct 19, 2026
ConsiderationCash
StructureNot stated
RegionEurope
Cross-borderYes
Contingent paymentNo
Overview
Merck KGaA, Darmstadt, Germany agreed to acquire Silence Therapeutics plc for $20.00 in cash per American Depositary Share, or $6.6667 per ordinary share, in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.
Deal rationale
The acquisition is intended to strengthen Merck KGaA, Darmstadt, Germany's capabilities to serve patients with targeted specialty and rare diseases and provide scale, resources and commercial capabilities to accelerate Divesiran's Phase 3 development.
AI-generated from the SEC filingPendingHealthcare › PharmaceuticalsUnited KingdomEurope
Timeline
Valuation and terms
| Equity value | $1.3B | |
|---|---|---|
| Enterprise value | $1.1B | Headline figure |
| Consideration | Cash |
Advisors
Buy-side
None listed
Sell-side
CPCenterview PartnersMSMorgan Stanley
Parties
Target
STSilence Therapeutics plc
- Headquarters
- United Kingdom
- Ticker
- —
Acquirer
MKMerck KGaA, Darmstadt, Germany
- Headquarters
- Germany
- Ticker
- —